Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes

Diabetes Care

Volumn 36, Issue SUPPL.2, 2013, Pages

  Burant, Charles F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CALCIUM; FASIGLIFAM; FATTY ACID; G PROTEIN COUPLED RECEPTOR 40; GLIMEPIRIDE; GLUCOSE; INSULIN; PLACEBO;

ARTICLE; BLOOD PRESSURE; CALCIUM CELL LEVEL; CELL STIMULATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; FAT INTAKE; FATTY ACID BLOOD LEVEL; GENETIC PREDISPOSITION; HUMAN; INSULIN RELEASE; INTRACELLULAR SIGNALING; LIPID ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING;

BENZOFURANS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MOLECULAR TARGETED THERAPY; RECEPTORS, G-PROTEIN-COUPLED; SULFONES;

EID: 84891812539     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS13-2037     Document Type: Article

References (55)

1. Jensen MV, Joseph JW, Ronnebaum SM, Burgess SC, Sherry AD, Newgard CB. Metabolic cycling in control of glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab 2008;295:E1287-E1297
2. Newsholme P, Gaudel C, McClenaghan NH. Nutrient regulation of insulin secretion and beta-cell functional integrity. Adv Exp Med Biol 2010;654:91-114
3. Stein DT, Esser V, Stevenson BE, et al. Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest 1996;97:2728-2735
4. Chang-Chen KJ, Mullur R, Bernal-Mizrachi E. Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord 2008;9: 329-343
5. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic b cell dedifferentiation as a mechanism of diabetic b cell failure. Cell 2012;150:1223-1234
6. McGarry JD, Brown NF. The mitochon-drial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 1997;244:1-14
7. Nolan CJ, Madiraju MS, Delghingaro-Augusto V, Peyot ML, Prentki M. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 2006;55(Suppl. 2): S16-S23
8. Roduit R, Nolan C, Alarcon C, et al. A role for the malonyl-CoA/long- chain acyl-CoA pathway of lipid signaling in the regulation of insulin secretion in response to both fuel and nonfuel stimuli. Diabetes 2004;53:1007-1019
9. Larsson O, Deeney JT, Bränström R, Berggren PO, Corkey BE. Activation of the ATP-sensitive K+ channel by long chain acyl-CoA. A role in modulation of pancreatic beta-cell glucose sensitivity. J Biol Chem 1996;271:10623-10626
10. Tarasov A, Dusonchet J, Ashcroft F. Metabolic regulation of the pancreatic beta-cell ATP-sensitive K+ channel: a pas de deux. Diabetes 2004;53(Suppl. 3):S113-S122
11. Bränström R, Aspinwall CA, Välimäki S, et al. Long-chain CoA esters activate human pancreatic beta-cell KATP channels: potential role in Type 2 diabetes. Dia-betologia 2004;47:277-283
12. Peter-Riesch B, Fathi M, Schlegel W, Wollheim CB. Glucose and carbachol generate 1, 2-diacylglycerols by different mechanisms in pancreatic islets. J Clin Invest 1988;81:1154-1161
13. Civelli O. GPCR deorphanizations: the novel, the known and the unexpected transmitters. Trends Pharmacol Sci 2005; 26:15-19
14. Morgan NG, Dhayal S. G-protein coupled receptors mediating long chain fatty acid signalling in the pancreatic beta-cell. Bio-chem Pharmacol 2009;78:1419-1427
15. Sawzdargo M, George SR, Nguyen T, Xu S, Kolakowski LF, O'Dowd BF. A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. Biochem Biophys Res Commun 1997;239:543-547
16. Briscoe CP, Tadayyon M, Andrews JL, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 2003; 278:11303-11311
17. Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003;422:173-176
18. Fujiwara K, Maekawa F, Yada T. Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am J Physiol Endo-crinol Metab 2005;289:E670-E677
19. Briscoe CP, Peat AJ, McKeown SC, et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 2006;148:619-628
20. Salehi A, Flodgren E, Nilsson NE, et al. Free fatty acid receptor 1 (FFA(1)R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. Cell Tissue Res 2005;322: 207-215
21. Zhang Y, Xu M, Zhang S, et al. The role of G protein-coupled receptor 40 in lipo-apoptosis in mouse beta-cell line NIT-1. J Mol Endocrinol 2007;38:651-661
22. Alquier T, Peyot ML, Latour MG, et al. Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 2009;58:2607-2615
23. Latour MG, Alquier T, Oseid E, et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007;56:1087-1094
24. Nagasumi K, Esaki R, Iwachidow K, et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 2009;58:1067-1076
25. Ferdaoussi M, Bergeron V, Zarrouki B, et al. G protein-coupled receptor (GPR) 40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 2012;55: 2682-2692
26. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in non-diabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003; 52:2461-2474
27. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 2005; 1:245-258
28. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, Poitout V. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 2008;57:2432-2437
29. Lan H, Hoos LM, Liu L, et al. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 2008;57:2999-3006
30. Alquier T, Poitout V. GPR40: good cop, bad cop? Diabetes 2009;58:1035-1036
31. Bharate SB, Rodge A, Joshi RK, et al. Discovery of diacylphloroglucinols as a new class of GPR40 (FFAR1) agonists. Bioorg Med Chem Lett 2008;18:6357-6361
32. Christiansen E, Urban C, Grundmann M, et al. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physico-chemical and in vitro ADME properties. J Med Chem 2011;54:6691-6703
33. Christiansen E, Urban C, Merten N, et al. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med Chem 2008;51:7061-7064
34. Garrido DM, Corbett DF, Dwornik KA, et al. Synthesis and activity of small molecule GPR40 agonists. Bioorg Med Chem Lett 2006;16:1840-1845
35. Hara T, Hirasawa A, Sun Q, et al. Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch Pharmacol 2009; 380:247-255
36. Houze JB, Zhu L, Sun Y, et al. AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorg Med Chem Lett 2012;22: 1267-1270
37. Humphries PS, Benbow JW, Bonin PD, et al. Synthesis and SAR of 1, 2, 3, 4-tetrahydroisoquinolin-1-ones as novel G-protein-coupled receptor 40 (GPR40) antagonists. Bioorg Med Chem Lett 2009; 19:2400-2403
38. McKeown SC, Corbett DF, Goetz AS, et al. Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor. Bioorg Med Chem Lett 2007;17:1584-1589
39. Mikami S, Kitamura S, Negoro N, et al. Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes. J Med Chem 2012;55:3756-3776
40. Naik H, Vakilynejad M, Wu J, et al. Safety, tolerability, pharmacokinetics, and phar-macodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 2012;52:1007-1016
41. Negoro N, Sasaki S, Ito M, et al. Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists. J Med Chem 2012;55:1538-1552
42. Negoro N, Sasaki S, Mikami S, et al. Optimization of (2, 3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent. J Med Chem 2012; 55:3960-3974
43. Sasaki S, Kitamura S, Negoro N, et al. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists. J Med Chem 2011;54:1365-1378
44. Song F, Lu S, Gunnet J, et al. Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists. J Med Chem 2007;50:2807-2817
45. Tan CP, Feng Y, Zhou YP, et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 2008;57: 2211-2219
46. Tsujihata Y, Ito R, Suzuki M, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 2011;339:228-237
47. Walsh SP, Severino A, Zhou C, et al. 3-Substituted 3-(4-aryloxyaryl)- propanoic acids asGPR40 agonists. Bioorg Med Chem Lett 2011;21:3390-3394
48. Yazaki R, Kumagai N, Shibasaki M. Cooperative activation of alkyne and thio-amide functionalities; direct catalytic asymmetric conjugate addition of terminal alkynes to a, b-unsaturated thio-amides. Chem Asian J 2011;6:1778-1790
49. Yazaki R, Kumagai N, Shibasaki M. Enan-tioselective synthesis of a GPR40 agonist AMG 837 via catalytic asymmetric conjugate addition of terminal alkyne to a, b-unsaturated thioamide. Org Lett 2011; 13:952-955
50. Zhang X, Yan G, Li Y, Zhu W, Wang H. DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats. Biomed Pharmacother 2010;64:647-651
51. Zhao Y, Song Y, Shen X, Liao J. Feasible Synthesis of Antagonist of GPR40 by Constructing 2-Thiouracil Ring viaAcid Mediated Cyclization. Heterocycles 2011; 83:1145-1151
52. Kotarsky K, Nilsson NE, Flodgren E, Owman C, Olde B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem Bio-phys Res Commun 2003;301:406-410
53. Leifke E, Naik H, Wu J, et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacody-namics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther 2012;92:29-39
54. Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012;379:1403-1411
55. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470